Find trials
Consejos para buscar

Stereotactic Radiation Therapy for Pediatric Sarcomas

Overview

Información sobre este estudio

The SBRT (stereotactic body radiation therapy) literature focuses on clinical outcomes in the adult population. However, SBRT (stereotactic body radiation therapy) has a particularly strong rationale for application in pediatrics given that high biologically effective doses have been shown to increase control in histologies, such as sarcoma, which are common in the pediatrics population (11,25). With stereotactic radiation therapy techniques, a reduction in normal tissue dose surrounding the target lesion of interest may also be accomplished resulting in lower toxicity. Given that pediatric patients with sarcomas, presenting with limited metastases in lung and bone, are still considered to be a curable population with aggressive local therapy, SBRT could have a significant impact on outcomes in oligometastatic patients who may be otherwise unresectable (25-28).

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • confirmed sarcoma of the soft tissue or bone
  • must have measurable disease via CT scan
  • tumor malignancies must meet certain criteria to be eligible
  • greater than 3 years of age
  • less than or equal to 40 years of age
  • life expectancy of at least 9 months
  • adequate performance status
  • ability to understand and willingness to sign informed consent document

Exclusion Criteria:

  • patients who have had chemotherapy or radiotherapy within 2 weeks prior to entering the study
  • patients who have had any prior radiotherapy to the treatment site(s)
  • patients may not participate on any other treatment protocol while they are receiving treatment on this protocol and for up to 3 months after these protocol treatments have ended
  • pregnant women
  • refusal of women of child bearing potential to take a pregnancy test prior to treatment

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Nadia Laack, M.D.

Cerrado para la inscripción

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

More information

Publicaciones

Publications are currently not available

Otros temas en investigación

.
CLS-20204242

Mayo Clinic Footer